MET in glioma: signaling pathways and targeted therapies

Aberrant methylation and silencing of the SPINT2 gene in high-grade gliomas

(2018) Tsuyoshi Fukushima et al.   CANCER SCIENCE

Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges

(2018) Ramesh Butti et al.   Molecular Cancer

Identification of genomic and molecular traits that present therapeutic vulnerability to HGF-targeted therapy in glioblastoma

(2018) Jason K Sa et al.   NEURO-ONCOLOGY

Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma

(2018) Mary Lou Affronti et al.   ONCOLOGIST

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine–DNA Methyltransferase Biomarker Analyses

(2017) Timothy Cloughesy et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy

(2017) Timothy F Cloughesy et al.   NEURO-ONCOLOGY

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy

(2017) Patrick Y Wen et al.   NEURO-ONCOLOGY

CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014

(2017) Quinn T Ostrom et al.   NEURO-ONCOLOGY

Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma

(2017) Eleanna Papa et al.   Cell Death & Disease

Crizotinib targets in glioblastoma stem cells

(2017) Audelaure Junca et al.   Cancer Medicine

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Effect of brefelamide on HGF-induced survival of 1321N1 human astrocytoma cells

(2016) Shigeyoshi Honma et al.   IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL

c-Met–mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma

(2016) Menggui Huang et al.   JOURNAL OF CLINICAL INVESTIGATION

Advances in HSP27 and HSP90-targeting strategies for glioblastoma

(2016) Randy van Ommeren et al.   JOURNAL OF NEURO-ONCOLOGY

Recurrent MET fusion genes represent a drug target in pediatric glioblastoma

(2016)   NATURE MEDICINE

Progress in glioma diagnosis, classification and treatment

(2016) Patrick Y. Wen et al.   Nature Reviews Neurology

Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models

(2016) Yuji Piao et al.   NEURO-ONCOLOGY

MET immunolabelling is a useful predictive tool forMETgene amplification in glioblastoma

(2016) F. Burel-Vandenbos et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Glycolipid GD3 and GD3 synthase are key drivers for glioblastoma stem cells and tumorigenicity

(2016) Shih-Chi Yeh et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma

(2016) Carl Koschmann et al.   Science Translational Medicine

Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein

(2015) Anna C. Navis et al.   ACTA NEUROPATHOLOGICA

Nuclear phosphorylated Y142 β-catenin accumulates in astrocytomas and glioblastomas and regulates cell invasion

(2015) Mireia Náger et al.   CELL CYCLE

miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma

(2015) Fotini M. Kouri et al.   GENES & DEVELOPMENT

High levels of c-Met is associated with poor prognosis in glioblastoma

(2015) Stine Asferg Petterson et al.   JOURNAL OF NEURO-ONCOLOGY

miR-144-3p exerts anti-tumor effects in glioblastoma by targeting c-Met

(2015) Fengming Lan et al.   JOURNAL OF NEUROCHEMISTRY

Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma

(2015) Jennifer Johnson et al.   Journal of Translational Medicine

The metalloprotease-disintegrin ADAM8 contributes to temozolomide chemoresistance and enhanced invasiveness of human glioblastoma cells

(2015) Fangyong Dong et al.   NEURO-ONCOLOGY

Survival and low-grade glioma: the emergence of genetic information

(2015) Elizabeth B. Claus et al.   Neurosurgical Focus

EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications

(2015) S A Greenall et al.   ONCOGENE

Gene mutations in gastric cancer: a review of recent next-generation sequencing studies

(2015) Y. Lin et al.   TUMOR BIOLOGY

Long noncoding RNA NEAT1 promotes glioma pathogenesis by regulating miR-449b-5p/c-Met axis

(2015) Li Zhen et al.   TUMOR BIOLOGY

TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations

(2014) M Labussière et al.   BRITISH JOURNAL OF CANCER

A novel lead compound CM-118

(2014) Lanfang Meng et al.   CANCER BIOLOGY & THERAPY

RNA-seq of 272 gliomas revealed a novel, recurrentPTPRZ1-METfusion transcript in secondary glioblastomas

(2014) Zhao-Shi Bao et al.   GENOME RESEARCH

Proteinase-activated receptor 1- and 4-promoted migration of Hep3B hepatocellular carcinoma cells depends on ROS formation and RTK transactivation

(2014) Franziska Mußbach et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (Volitinib) as a Highly Potent and Selective Mesenchymal–Epithelial Transition Factor (c-Met) Inhibitor in Clinical Development for Treatment of Cancer

(2014) Hong Jia et al.   JOURNAL OF MEDICINAL CHEMISTRY

MGMT testing—the challenges for biomarker-based glioma treatment

(2014) Wolfgang Wick et al.   Nature Reviews Neurology

Targeting MET for glioma therapy

(2014) Ahmed J. Awad et al.   Neurosurgical Focus

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

DNA double-strand breaks cooperate with loss of Ink4 and Arf tumor suppressors to generate glioblastomas with frequent Met amplification

(2014) C V Camacho et al.   ONCOGENE

The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme

(2013) O. F. Olmez et al.   Clinical & Translational Oncology

Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistance

(2013) A. Jahangiri et al.   CLINICAL CANCER RESEARCH

EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma

(2013) L Li et al.   ONCOGENE

Effects of Dual Targeting of Tumor Cells and Stroma in Human Glioblastoma Xenografts with a Tyrosine Kinase Inhibitor against c-MET and VEGFR2

(2013) Anna C. Navis et al.   PLoS One

Inhibition of EGFR Induces a c-MET-Driven Stem Cell Population in Glioblastoma

(2013) Hyun Jung Jun et al.   STEM CELLS

An Orally Bioavailable c-Met Kinase Inhibitor Potently Inhibits Brain Tumor Malignancy and Growth

(2012) Fadila Guessous et al.   Anti-Cancer Agents in Medicinal Chemistry

METGain in Diffuse Astrocytomas is Associated with Poorer Outcome

(2012) Daniela Pierscianek et al.   BRAIN PATHOLOGY

VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex

(2012) Kan V. Lu et al.   CANCER CELL

MET Signaling Regulates Glioblastoma Stem Cells

(2012) K. M. Joo et al.   CANCER RESEARCH

Targeting the TGFβ signalling pathway in disease

(2012) Rosemary J. Akhurst et al.   NATURE REVIEWS DRUG DISCOVERY

Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells

(2012) Kang Ho Kim et al.   NEURO-ONCOLOGY

Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation

(2012) H Yang et al.   ONCOGENE

17AEP-GA, an HSP90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion

(2012) KATARZYNA MIEKUS et al.   ONCOLOGY REPORTS

Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors

(2012) Barbara Sennino et al.   Cancer Discovery

Expression of GD2 and GD3 Gangliosides in Human Embryonic Neural Stem Cells

(2011) Makoto Yanagisawa et al.   ASN Neuro

Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases

(2011) Wei Xu et al.   CANCER CELL

Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma

(2011) Matija Snuderl et al.   CANCER CELL

A Novel Kinase Inhibitor, INCB28060, Blocks c-MET-Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3

(2011) X. Liu et al.   CLINICAL CANCER RESEARCH

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma

(2011) P. Y. Wen et al.   NEURO-ONCOLOGY

Acquired MET expression confers resistance to EGFR inhibition in a mouse model of glioblastoma multiforme

(2011) H J Jun et al.   ONCOGENE

Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma

(2011) Q. Xie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype

(2011) Y. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma

(2010) E. G. Van Meir et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

CD44 Attenuates Activation of the Hippo Signaling Pathway and Is a Prime Therapeutic Target for Glioblastoma

(2010) Y. Xu et al.   CANCER RESEARCH

Phase II Evaluation of Gefitinib in Patients With Newly Diagnosed Grade 4 Astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074

(2010) Joon H. Uhm et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

c-Met expression is associated with time to recurrence in patients with glioblastoma multiforme

(2010) Wei Liu et al.   JOURNAL OF CLINICAL NEUROSCIENCE

HGF upregulates CXCR4 expression in gliomas via NF-κB: implications for glioma cell migration

(2010) Mine Esencay et al.   JOURNAL OF NEURO-ONCOLOGY

IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas

(2009) Takuya Watanabe et al.   AMERICAN JOURNAL OF PATHOLOGY

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

MicroRNA-34a Inhibits Glioblastoma Growth by Targeting Multiple Oncogenes

(2009) Y. Li et al.   CANCER RESEARCH

Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

(2009) J. P. Eder et al.   CLINICAL CANCER RESEARCH

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

Malignant Gliomas in Adults

(2008) Patrick Y. Wen et al.   NEW ENGLAND JOURNAL OF MEDICINE

SOX2Silencing in Glioblastoma Tumor-Initiating Cells Causes Stop of Proliferation and Loss of Tumorigenicity

(2008) Rosaria Maria Rita Gangemi et al.   STEM CELLS